#mcrpc 検索結果
#ESMO25 @drlouiseemmett dives into imaging-based theranostics in #mCRPC 📊 In TheraP: • PSMA SUVmean ↑ → PSA50 response ↑ (29% → 89%) • SUVmean also linked to OS 🧬 ENZA-p: PSMA-TTV predicts OS w/ enzalutamide PSMA-(TTV and SUVmean useful in identifying pts most likely to…
Phase 1 study of QLH12016, an androgen receptor PROTAC degrader in heavily pretreated patients with #mCRPC: Safety, tolerability, and antitumor activity. Presentation by Shun Zhang. #ESMO25 written coverage by @zklaassen_md > bit.ly/3JfYUQf @myESMO @neerajaiims
Oral at #IUCS25: 1L mCRPC: Ola+Abi beats Doc in rPFS (14.5 vs 8.2 mo) in a retrospective cohort. @MicheleMaffezz @OncoAlert #mCRPC #urooncology
A randomized phase II study of 177Lu-PSMA-617 vs docetaxel in patients with #mCRPC and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21. Presentation by Kim Chi, MD. @VanProstateCtr. #ESMO25 written coverage by @RKSayyid @UAUrology > bit.ly/471qxpp…
Opportunities to optimize the systemic treatment for #mCRPC in low-income countries: a seven-years analysis of the Brazilian public health system. Presentation by Fernando Monteiro, MD. #ESMO25 written coverage by @chavarriagaj > bit.ly/4opARgH @myESMO
Optimized use of immunotherapy and targeted therapies in #mCRPC. Presentation by @AOmlin. #ESMO25 written coverage by @RKSayyid > bit.ly/47nUjnl @myESMO @neerajaiims
Dose-escalation + expansion trial of fractionated and multiple-dose PSMA-targeted alpha radionuclide 225Ac-J591 for #mCRPC. Presentation by @DrScottTagawa @WeillCornell. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/473HiQZ @myESMO
#ESMO24 Quick Take Insights: A Focus on the #PEACE3Study PEACE-3 shows that combining radium-223 with enzalutamide boosts rPFS and OS in first-line #mCRPC with bone metastases. Notably, this combo, alongside bone-protective agents, may now be a viable 1st-line treatment for mCRPC…
A ten-year perspective on radium-223 in #mCRPC: Survival, symptom control, and lessons learned. Presentation by Josette Staufert-Gutierrez, MD. #ESMO25 written coverage by @zklaassen_md > bit.ly/3L2NHTI @myESMO
It is this time of the Year again: 10 TOP TRANSLATIONAL PAPERS IN GU ONCOLOGY! 1/ Prostate Paper 1 Fonseca et al. introduced a machine-learning approach that predicts whether patients with #mCRPC have sufficient ctDNA% for informative genotyping. This study addresses a critical…
Biomarker analyses from the phase II PT-112 monotherapy study in late-line #mCRPC. Presentation by @RoubaudG. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/3KVb3uF @myESMO @neerajaiims
Lutetium-177 outperforms cabazitaxel in #mCRPC: Real-world Flatiron database analysis. @ziremozay @huntsmancancer joins @neerajaiims discussing a comparative effectiveness study of lutetium-177 vs cabazitaxel in metastatic castration-resistant #ProstateCancer. #WatchNow >…
Final analysis of patients treated with 177Lu-PSMA-617 in early access program in #mCRPC in #France. Presentation by Vincent Massard. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4owzb5f @myESMO @neerajaiims
#DAROTAXEL: A randomized, multicenter, phase II trial of docetaxel or cabazitaxel with or without darolutamide in patients with #mCRPC. Presentation by Tanja Van Dijk @ErasmusMC. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/3L4aNt7 @myESMO…
Mevrometostat + Enzalutamide vs E alone in #mCRPC: improved rPFS (HR 0.51), OR (26.7% vs. 14.3%) and PSA50: (34.1% vs. 15.4%). Manageable safety profile! @MikeSchweizerMD @ASCO #GU25 @OncoAlert
Real-world experience with radium-223 in #mCRPC: a single-center retrospective analysis. Presentation by Giorgia Bortolus. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/47xgZmf @myESMO @neerajaiims
Efficacy and safety of 177Lu-PSMA-617 (LuPSMA) in elderly patients with #mCRPC. Presented by @AvinaRami @BrighamWomens. #EMSO25 written coverage by @chavarriagaj @UofT > bit.ly/46Y0orE @myESMO @neerajaiims
CELC-G-201: Phase 1/2 study of gedatolisib in combination with darolutamide in #mCRPC. Presentation by Alice Bernard-Tessier, MD @GustaveRoussy. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/47btLpa @myESMO @neerajaiims
TiP – The #ARTISAN Trial: Phase 1/2 dose escalation and expansion of AB001 in patients with #mCRPC. Presentation by Oliver Sartor, MD @EJHospital. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/46YBTKW @myESMO @neerajaiims
Lutetium-177 outperforms cabazitaxel in #mCRPC: Real-world Flatiron database analysis. @ziremozay @huntsmancancer joins @neerajaiims discussing a comparative effectiveness study of lutetium-177 vs cabazitaxel in metastatic castration-resistant #ProstateCancer. #WatchNow >…
What does a proactive approach to #mCRPC treatment look like? 📊 Dr. Benjamin H. Lowentritt shares his insights on supporting the immune system to help patients achieve the best possible outcomes. Watch now ▶️ : brnw.ch/21wXg4D #PatientCare #Immunotherapy
#ESMO24 Quick Take Insights: A Focus on the #PEACE3Study PEACE-3 shows that combining radium-223 with enzalutamide boosts rPFS and OS in first-line #mCRPC with bone metastases. Notably, this combo, alongside bone-protective agents, may now be a viable 1st-line treatment for mCRPC…
#HSPC to #mCRPC: Management current approaches and future developments. @uromc & @drjefstathiou join @zklaassen_md to discuss advances and future directions in advanced prostate cancer management. #WatchNow on UroToday > bit.ly/44bLEUF
Impact of bone-protecting agents on outcomes with enzalutamide, with or without radium-223, in asymptomatic/mildly symptomatic patients with bone #mCRPC from PEACE-3. Presentation by Murilo de Almeida Luz, MD. #WSAUA25 written coverage by @zklaassen_md > bit.ly/47FkMwC…
Understanding immunotherapy outcomes in advanced prostate cancer is critical for treatment planning. From @mnt, read about what you need to know regarding the success rate of #Immunotherapy for prostate cancer. 🔗 brnw.ch/21wXbPs #ProstateCancer #mCRPC #Oncology
November is #ProstateCancerAwarenessMonth 💙 At K36, we’re committed to advancing new options for men with metastatic castration-resistant prostate cancer through our NSD2 inhibitor #KTX2001. Learn more about KTX-2001 NCT07103018 #mCRPC #Oncology #ProstateCancer #K36 #NSD2
What happens when prostate cancer progresses? #mCRPC represents an advanced stage of prostate cancer that poses unique challenges in treatment. 🔗 Learn more about mCRPC: brnw.ch/21wX3Zv
New #Uromigos update! We explore how antibody drug conjugates and bispecific ABs are redefining #mCRPC treatment - from PSMA & B7-H3 ADCs to next gen T-cell engaged. Precision meets immune activation. Watch here 👇 linkedin.com/posts/uromigos… @Uromigos @DrChoueiri @neerajaiims…
📢 Ph1/2 HLD-0915 (first-in-class oral RIPTAC) in #mCRPC ✅ Novel mechanism of action ✅ Well tolerated, manageable safety ✅ Clinical activity in pts with AR and non-AR genetic alterations ➡️ Proof-of-concept for RIPTACs #Targets25
Terbium-161 vs lutetium-177: Comparing next-gen radioligands for #ProstateCancer. @DrMHofman @PeterMacCC joins Oliver Sartor, MD @EJHospital to discuss the #VIOLET study evaluating Terbium-161 PSMA therapy in #mCRPC. #WatchNow > bit.ly/46AXlG8
The dose-escalation trial of 225Ac-J591 sounds exciting, offering potential new hope for #mCRPC treatment. I'm curious how the fractionated and multiple-dose administration impacts both efficacy and safety. Can @DrScottTagawa share more about any interim results or patient…
Dose-escalation + expansion trial of fractionated and multiple-dose PSMA-targeted alpha radionuclide 225Ac-J591 for #mCRPC. Presentation by @DrScottTagawa @WeillCornell. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/473HiQZ @myESMO
Retreatment with 177Lu-PSMA-617 in #mCRPC patients treated under the #French early access program. Presetation by Philippe Barthelemy, MD. #ESMO25 written coverage by @zklaassen_md > bit.ly/4o44rZw @myESMO @neerajaiims
Final analysis of patients treated with 177Lu-PSMA-617 in early access program in #mCRPC in #France. Presentation by Vincent Massard. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4owzb5f @myESMO @neerajaiims
Optimized use of immunotherapy and targeted therapies in #mCRPC. Presentation by @AOmlin. #ESMO25 written coverage by @RKSayyid > bit.ly/47nUjnl @myESMO @neerajaiims
A randomized phase II study of 177Lu-PSMA-617 vs docetaxel in patients with #mCRPC and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21. Presentation by Kim Chi, MD. @VanProstateCtr. #ESMO25 written coverage by @RKSayyid @UAUrology > bit.ly/471qxpp…
Opportunities to optimize the systemic treatment for #mCRPC in low-income countries: a seven-years analysis of the Brazilian public health system. Presentation by Fernando Monteiro, MD. #ESMO25 written coverage by @chavarriagaj > bit.ly/4opARgH @myESMO
TiP – The #ARTISAN Trial: Phase 1/2 dose escalation and expansion of AB001 in patients with #mCRPC. Presentation by Oliver Sartor, MD @EJHospital. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/46YBTKW @myESMO @neerajaiims
#DAROTAXEL: A randomized, multicenter, phase II trial of docetaxel or cabazitaxel with or without darolutamide in patients with #mCRPC. Presentation by Tanja Van Dijk @ErasmusMC. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/3L4aNt7 @myESMO…
Phase 1 study of QLH12016, an androgen receptor PROTAC degrader in heavily pretreated patients with #mCRPC: Safety, tolerability, and antitumor activity. Presentation by Shun Zhang. #ESMO25 written coverage by @zklaassen_md > bit.ly/3JfYUQf @myESMO @neerajaiims
Optimized use of immunotherapy and targeted therapies in #mCRPC. Presentation by @AOmlin. #ESMO25 written coverage by @RKSayyid > bit.ly/47nUjnl @myESMO @neerajaiims
Opportunities to optimize the systemic treatment for #mCRPC in low-income countries: a seven-years analysis of the Brazilian public health system. Presentation by Fernando Monteiro, MD. #ESMO25 written coverage by @chavarriagaj > bit.ly/4opARgH @myESMO
A randomized phase II study of 177Lu-PSMA-617 vs docetaxel in patients with #mCRPC and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21. Presentation by Kim Chi, MD. @VanProstateCtr. #ESMO25 written coverage by @RKSayyid @UAUrology > bit.ly/471qxpp…
A ten-year perspective on radium-223 in #mCRPC: Survival, symptom control, and lessons learned. Presentation by Josette Staufert-Gutierrez, MD. #ESMO25 written coverage by @zklaassen_md > bit.ly/3L2NHTI @myESMO
#ESMO25 @drlouiseemmett dives into imaging-based theranostics in #mCRPC 📊 In TheraP: • PSMA SUVmean ↑ → PSA50 response ↑ (29% → 89%) • SUVmean also linked to OS 🧬 ENZA-p: PSMA-TTV predicts OS w/ enzalutamide PSMA-(TTV and SUVmean useful in identifying pts most likely to…
Dose-escalation + expansion trial of fractionated and multiple-dose PSMA-targeted alpha radionuclide 225Ac-J591 for #mCRPC. Presentation by @DrScottTagawa @WeillCornell. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/473HiQZ @myESMO
Oral at #IUCS25: 1L mCRPC: Ola+Abi beats Doc in rPFS (14.5 vs 8.2 mo) in a retrospective cohort. @MicheleMaffezz @OncoAlert #mCRPC #urooncology
Biomarker analyses from the phase II PT-112 monotherapy study in late-line #mCRPC. Presentation by @RoubaudG. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/3KVb3uF @myESMO @neerajaiims
Mevrometostat + Enzalutamide vs E alone in #mCRPC: improved rPFS (HR 0.51), OR (26.7% vs. 14.3%) and PSA50: (34.1% vs. 15.4%). Manageable safety profile! @MikeSchweizerMD @ASCO #GU25 @OncoAlert
#DAROTAXEL: A randomized, multicenter, phase II trial of docetaxel or cabazitaxel with or without darolutamide in patients with #mCRPC. Presentation by Tanja Van Dijk @ErasmusMC. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/3L4aNt7 @myESMO…
Final analysis of patients treated with 177Lu-PSMA-617 in early access program in #mCRPC in #France. Presentation by Vincent Massard. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4owzb5f @myESMO @neerajaiims
Real-world experience with radium-223 in #mCRPC: a single-center retrospective analysis. Presentation by Giorgia Bortolus. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/47xgZmf @myESMO @neerajaiims
TiP – The #ARTISAN Trial: Phase 1/2 dose escalation and expansion of AB001 in patients with #mCRPC. Presentation by Oliver Sartor, MD @EJHospital. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/46YBTKW @myESMO @neerajaiims
💫🌟Pembrolizumab ➕Olaparib for Patients W/ Previously Tx and Biomarker-Unselected #mCRPC: Randomized, Open-Label, P III #KEYLYNK010 🌟💫 📊 RESULTS 1️⃣793 participants 🧑🔬 2️⃣PEMBRO + olaparib 💙🧬 vs. NHA ❤️🔍 3️⃣HRR & BRCA mutations detected 4️⃣Median time from random: 12.7 ms…
#ESMO24 Quick Take Insights: A Focus on the #PEACE3Study PEACE-3 shows that combining radium-223 with enzalutamide boosts rPFS and OS in first-line #mCRPC with bone metastases. Notably, this combo, alongside bone-protective agents, may now be a viable 1st-line treatment for mCRPC…
CELC-G-201: Phase 1/2 study of gedatolisib in combination with darolutamide in #mCRPC. Presentation by Alice Bernard-Tessier, MD @GustaveRoussy. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/47btLpa @myESMO @neerajaiims
Nice summary of “game changing” improvements in OS with addition of PARPi to ADT+ARSI in #mCRPC by @FSchlurmann at #EMUC23 Interesting discussion re: 🧬 genetic testing 💊 role of PARPi in non-HRR subgroups 🫀 importance of assessing risk of cardiovascular toxicity of ARSIs
It is this time of the Year again: 10 TOP TRANSLATIONAL PAPERS IN GU ONCOLOGY! 1/ Prostate Paper 1 Fonseca et al. introduced a machine-learning approach that predicts whether patients with #mCRPC have sufficient ctDNA% for informative genotyping. This study addresses a critical…
PCPro as a prognostic plasma lipidomic biomarker in #TheraP (ANZUP 1603): a randomized trial of 177Lu-PSMA-617 vs cabazitaxel in #mCRPC. Presentation by Tahlia Scheinberg, MD @Sydney_Uni. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/49cy1r3 @myESMO…
Something went wrong.
Something went wrong.
United States Trends
- 1. Grammy 369K posts
- 2. #FliffCashFriday 1,270 posts
- 3. Dizzy 10.2K posts
- 4. Clipse 21.8K posts
- 5. James Watson 5,938 posts
- 6. #NXXT 1,100 posts
- 7. Kendrick 63.7K posts
- 8. #GOPHealthCareShutdown 8,958 posts
- 9. #FursuitFriday 12.3K posts
- 10. Orban 44.1K posts
- 11. Thune 73.6K posts
- 12. Chase 88.5K posts
- 13. Darryl Strawberry 1,030 posts
- 14. Leon Thomas 21.5K posts
- 15. Carmen 48.1K posts
- 16. addison rae 25.3K posts
- 17. AOTY 22.7K posts
- 18. Alfredo 2 1,088 posts
- 19. olivia dean 16.3K posts
- 20. Katseye 122K posts